A treasure of pharmacogenomic insights into postprandial lipoproteinemia and therapeutic responses to fibrate therapy: lessons from GOLDN.
Division of Cardiovascular Medicine, University of Michigan Hospital, 1500 E. Medical Center Drive, SPC 5853, Ann Arbor, MI 48109-5853, USA. rrosenso@umich.edu
Robert S
RS
Rosenson
D000072040:Apolipoprotein A-V; D001054:Apolipoproteins A / Q000235:genetics*; D008076:Cholesterol, HDL / Q000097:blood / Q000235:genetics; D011345:Fenofibrate / Q000494:pharmacology*; D005838:Genotype; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008074:Lipoproteins / Q000097:blood* / Q000235:genetics; D010597:Pharmacogenetics; D019518:Postprandial Period; D014280:Triglycerides / Q000097:blood / Q000235:genetics
C437704:APOA5 protein, human; D000072040:Apolipoprotein A-V; D001054:Apolipoproteins A; D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D014280:Triglycerides; D011345:Fenofibrate